CULTURE
We are cancer-fighting pioneers,
guided by an epic purpose.
Living life to the fullest.
WATCH OUR EPIC STORY VIDEO
“Knowledge is empowerment, both to patients and employees.”
– LINCY CHU, ALLIANCE MANAGER
CORE VALUES
Principled
PATIENT-FOCUSED
COMMITTED TO EXCELLENCE
INNOVATIVE
COLLABORATIVE
COURAGEOUS
DIVERSITY & INCLUSION
Our commitment to our people and our community
Epic Sciences’ Diversity and Inclusion Action Team
The San Marcos Promise Partnership
Epic Sciences is proud to be partnering with The San Marcos Promise, a nonprofit foundation working to connect education, business, and community leaders to impact student futures. SMP’s programs target students in the San Marcos Unified School District (SMUSD), where 69% of the 21,000 K-12 students are students of color, and 41.7% of students qualify for the free or reduced meal program.
SMP’s goal is to help SMUSD students discover their interests and strengths and take the necessary steps to prepare for a successful career. With a STEM-focus, SMP’s programs have the potential to increase college enrollment rates among all students and increase entry-level wages for students directly joining the workforce. Epic Sciences’ volunteers will partner with SMP to provide mentoring, career advice, and coaching to students.
CAREERS
LEADERSHIP
Lloyd Sanders joined Epic Sciences as President and Chief Executive Officer in 2019 with more than 20 years of diagnostics and pharmaceutical industry experience, most of it focused on oncology. Prior to joining Epic, he served as president of the oncology segment of Myriad Genetics, overseeing the oncology, urology and dermatology commercial organizations. While at Myriad, he was responsible for the sales, marketing, medical, customer service and laboratory operations for numerous market-leading commercial products, including molecular diagnostics for risk assessment, diagnosis/screening, prognosis and selection of therapies for breast, prostate, colorectal and other cancers.
Previously, Mr. Sanders served as chief operating officer at Dey Pharma, a division of Mylan, overseeing sales, marketing and medical affairs, including the EpiPen® flagship brand. Prior to Dey Pharma, he held several leadership positions including responsibility for the commercial growth of a number of oncology products at Sanofi-Synthelabo, subsequently Sanofi-Aventis, where he led the successful restructuring and integration of two companies’ sales forces after the merger. Mr. Sanders started his pharmaceutical career and participated in oncology product launches at Pharmacia (now Pfizer).
Mr. Sanders earned a Bachelor’s business degree with an emphasis in marketing from Memphis State University.
Mark Aguillard joined Epic Sciences as the General Manager of the Oncology Business Unit in 2021 with over 20 years of experience driving commercial growth in the genomics, pharmaceutical, and biotechnology industries. Prior to joining Epic, he served in commercial leadership roles with Myriad Genetics, binx health, OmniSeq, and Eli Lilly & Company with a breadth of commercial experience in leading sales, marketing, customer service, and managed care teams across oncology and women’s health. Over the course of his career, Mr. Aguillard launched the first pan-cancer hereditary cancer panel, myRisk, built multiple sales and marketing teams, led the integration of two multi-million dollar companies, and secured coverage and reimbursement for multiple novel diagnostic products. Mr. Aguillard received his Bachelors in Business Administration with a major in Finance from Texas Tech University.
Martin Blankfard joined Epic Sciences as the Vice President of Strategic Initiatives in 2019. Martin has over 30 years of platform development experience in both veterinary and IVD clinical diagnostics across startup, mid-size, and large companies. He has in-depth knowledge in multiple immunoassay diagnostic platforms including ELISA, IHC, Electro-Chemi and Chemiluminescent, lateral flow, flow cytometry, Luminex, and many forms of cell-based technologies. During his 30-year tenure Martin has led R&D, product management, business development, and operations. Martin holds a B.S. Degree in Food Science and a Master of Science Degree in Physiology from the University of Maryland.
Amara Siva, Ph.D. joined Epic Sciences as the Vice President of Lab Operations in 2021. Dr. Siva has over 20 years of molecular diagnostic development experience, including assay development from concept stage to clinical validation, and the launch and scaling of molecular and immunologic diagnostic tests into commercial clinical laboratories as well as implementation into global clinical trials. Prior to joining Epic Sciences, Dr. Siva served in leadership roles in CLIA laboratory operations management, clinical trials, and research at companies including Pathnostics, Millennium Health, Genoptix/Novartis, Gen-Probe, and Alexion. Dr. Siva received her B.S. in Biochemistry and Cell Biology from UC San Diego and Ph.D. in Biological Chemistry from UCLA. She is an ASQ-certified Six Sigma Green Belt, holds a Clinical Genetic Molecular Biologist Scientist license in the State of California, and is certified as a High-complexity Clinical Laboratory Director by the American Board of Bioanalysis.
IN MEMORY
In memory of Jason Christiansen, Ph.D., who served as the Chief Technology Officer of Epic Sciences. Jason was an instrumental leader in the launch of DefineMBC, a novel liquid biopsy test to improve care for patients battling metastatic breast cancer. For more than 20 years he dedicated his career to research & development work that advanced healthcare and personalized medicine. We honor his commitment to improving the lives of patients and we will continue the work of advancing care for patients with cancer.